Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of “Hold” by Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX) has been assigned an average rating of “Hold” from the nine analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $27.22.

Several brokerages have commented on PCRX. Needham & Company LLC raised their price objective on Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Barclays lifted their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price target for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Finally, HC Wainwright lifted their price objective on Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, February 28th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC lifted its holdings in shares of Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock worth $26,000 after buying an additional 1,208 shares in the last quarter. Ancora Advisors LLC purchased a new stake in Pacira BioSciences in the 4th quarter worth $26,000. Caitlin John LLC boosted its holdings in shares of Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after purchasing an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after purchasing an additional 2,749 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after purchasing an additional 513 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Trading Up 0.8 %

PCRX opened at $22.87 on Monday. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.27 and a beta of 0.86. The business has a 50 day simple moving average of $23.96 and a two-hundred day simple moving average of $19.25. Pacira BioSciences has a one year low of $11.16 and a one year high of $31.67. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.